Johnson & Johnson delivered better-than-expected financial results for the third quarter, propelled by robust momentum in its pharmaceutical division that helped counteract softer demand across its medical technology portfolio. The healthcare powerhouse reported quarterly revenue of $25.4 billion and adjusted earnings per share of $2.59, surpassing consensus expectations. On the heels of this resilient performance, the company lifted its full-year earnings and sales guidance, signaling confidence in its high-margin treatment pipeline.

The pharmaceutical business served as the primary growth engine, expanding 7.7% year-over-year to $16.76 billion. Highlighting the segment’s strength was immunology powerhouse Tremfya, which surged 68% to reach $2.4 billion in quarterly revenue, comfortably beating projections. This impressive surge has played a vital role in cushioning the decline of Stelara, whose sales plummeted 54% to $716 million amid escalating competition from biosimilar therapies. Oncology treatment Darzalex also contributed notable gains, climbing 16% to $4.24 billion.

In contrast, the medical technology unit encountered regional and geopolitical friction, with division sales inching up just 2.5% to $8.6 billion—falling short of market projections. Outside the United States, medical device revenue remained broadly flat. Leadership noted that shifting budget priorities in the Middle East have weighed on demand, as regional nations reallocate capital toward defense amid ongoing conflict, delaying procurement in otherwise high-end healthcare systems. Furthermore, procedural softness in cardiovascular surgery and lingering regulatory scrutiny surrounding Abiomed’s Impella heart pumps continued to dampen equipment sales.

Looking ahead, Johnson & Johnson is moving forward with strategic restructuring by advancing plans to carve out its orthopedics branch, DePuy Synthes. Management emphasized that solid balance-sheet flexibility eliminates any urgency for an unfavorable transaction, keeping options open for an independent separation targeted around mid-2027 or a structured deal. Apollo Global Management has reportedly expressed interest in acquiring the unit at a valuation near $20 billion, highlighting significant investor appetite as the conglomerate streamlines its core operations.

Key Takeaways

• Johnson & Johnson posted third-quarter revenue of $25.4 billion and adjusted EPS of $2.59, exceeding Wall Street targets and prompting an upward revision to full-year guidance.
• Tremfya sales jumped 68% to $2.4 billion, effectively mitigating steep revenue declines from Stelara following loss of exclusivity.
• Medical technology sales missed estimates at $8.6 billion due to device headwinds, procedural delays, and defense budget reallocations in the Middle East.

Editor’s Analysis & Impact

Johnson & Johnson’s latest quarterly numbers illustrate a classic portfolio transition under patent cliff pressures. The market feared a steep decline as blockbuster drug Stelara faced aggressive biosimilar competition, but the explosive 68% growth in Tremfya demonstrates that the company’s life-cycle management and new indications in inflammatory bowel disease are working effectively. Meanwhile, the softer performance in MedTech highlights broader macroeconomic vulnerabilities, specifically geopolitical turbulence reshaping public spending priorities in emerging and Middle Eastern markets. Moving forward, divesting the slower-growth DePuy Synthes orthopedics division should unlock higher margins and allow Johnson & Johnson to trade at a premium closer to pure-play biopharma peers, assuming it continues navigating heart pump device inquiries and international pricing reforms effectively.

Frequently Asked Questions

Q: Why did Johnson & Johnson raise its full-year outlook?
A: The company raised its full-year guidance after delivering stronger-than-expected third-quarter revenue and net income, largely driven by outperformance in its innovative medicine portfolio.

Q: How did Middle East tensions impact Johnson & Johnson's medical device sales?
A: Geopolitical conflict in the region led key markets such as Saudi Arabia and the UAE to divert healthcare capital budgets toward national defense, dampening demand for elective surgeries and premium medical devices.

Q: What is the status of Johnson & Johnson's orthopedics spinoff?
A: Johnson & Johnson plans to spin off or sell DePuy Synthes by approximately mid-2027, with private equity interest from firms like Apollo Global Management valuing the unit near $20 billion.